Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Interest Expenses (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Interest Expenses for 16 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 4.43% year-over-year to $11.4 million, compared with a TTM value of $46.2 million through Dec 2025, down 6.93%, and an annual FY2025 reading of $46.2 million, down 6.93% over the prior year.
  • Interest Expenses was $11.4 million for Q4 2025 at Amicus Therapeutics, down from $11.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $13.0 million in Q3 2023 and bottomed at $8.0 million in Q1 2021.
  • Average Interest Expenses over 5 years is $10.8 million, with a median of $11.5 million recorded in 2025.
  • The sharpest move saw Interest Expenses surged 124.21% in 2021, then dropped 7.89% in 2025.
  • Year by year, Interest Expenses stood at $8.2 million in 2021, then surged by 35.9% to $11.1 million in 2022, then increased by 15.61% to $12.8 million in 2023, then dropped by 6.77% to $12.0 million in 2024, then dropped by 4.43% to $11.4 million in 2025.
  • Business Quant data shows Interest Expenses for FOLD at $11.4 million in Q4 2025, $11.7 million in Q3 2025, and $11.6 million in Q2 2025.